Live Breaking News & Updates on Patient selection

Stay informed with the latest breaking news from Patient selection on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Patient selection and stay connected to the pulse of your community

iTWire - Why clinical trial patient recruitment software matters

GUEST OPINION: In the evolving realm of healthcare, technological advancements are profoundly impacting facets of clinical research. A notable domain...

Enhancing-recruitment-efficiency , Patient-selection , Operational-effectiveness , Boost-patient-engagement , Patient-onboarding , Trial-success , Data-management , Data-storage , Data-analysis , Technology-news , Ech-news

Simple hysterectomy not inferior for pelvic recurrence in cervical cancer

Simple hysterectomy not inferior for pelvic recurrence in cervical cancer
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Canada , Pedrot-ramirez , Marie-plante , Centre-hospitalier-universitaire-de-qu , New-england-journal , Radical-hysterectomy , Low-risk-cervical-cancer , Less-is-more , Patient-selection ,

Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

Experts discuss the impact of elacestrant on patient well-being, including potential cardiovascular and gastrointestinal toxicities, quality of life, and patient feedback regarding access to treatment.

William-gradishar , Gregory-vidal , Rena-callahan , Mabel-mardones , Peer-exchange , European-society-for-medical-oncology-congress , Medical-oncology-congress , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances

Elacestrant: Treatment Considerations, Including Dosing and Compliance

Experts explore treatment considerations when treating patients with metastatic breast cancer with elacestrant, including dosing, patient selection, adherence, and treatment duration. Participants also discuss dose modifications, adherence concerns, and how they determine treatment failure.

William-gradishar , Mabel-mardones , Rena-callahan , Gregory-vidal , Peer-exchange , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive

Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.

Rena-callahan , William-gradishar , Mabel-mardones , Gregory-vidal , Peer-exchange , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive

ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection.

William-gradishar , Rena-callahan , Mabel-mardones , Gregory-vidal , Peer-exchange , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive

Optimizing BCMA-Targeted CAR-T Therapies: Patient Selection, Clinical Impact, and Treatment Sequencing

Experts delve into the optimal positioning of BCMA-targeted CAR-T therapies in the treatment plan for Relapsed/Refractory Multiple Myeloma (R/R MM), providing valuable perspectives on strategic considerations in myeloma care.

Refractory-multiple-myeloma , Patient-selection , Clinical-impact , Multiple-myeloma , Relapsed-refractory-multiple-myeloma , Ash-2023 , Rr-mm , Bcma-targeted-car-t , Car-t , Cart-cell-therapy , Multiple-myeloma-treatment

Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

Experts discuss how they determine whether a patient with metastatic breast cancer is a candidate for treatment with elacestrant based on FDA approved indication, NCCN guidelines, and the results of ESR1 mutation and resistance marker testing. Participants also discuss how they determine treatment failure or resistance.

Breast-cancer , Clinical-guidelines , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive , Her2-negative , Selective-estrogen-receptor-degrader

Triple Combination Therapies in RCC: Clinical Trial Insights

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

Optimizing-therapy , Advanced-renal-cell-carcinoma , Combination-therapies , Clinical-trial-insights , Renal-cell-carcinoma , Advanced-rcc , Metastatic-rcc , Kidney-cancer , Triple-combination-therapies , Cosmic-313 , Clinical-trials

New Mercies: Ria Bos - Mercy Ships

In this episode, Ria shares how Mercy Ships finds patients for surgery, the hope that is offered each person, and a night she’ll never forget.

Uganda , Netherlands , Madagascar , Texas , United-states , Australia , Sierra-leone , Ukraine , Malagasy , Raeanne-newquist , Ministry-of-health , Mercy-ships